1. Application or a pharmaceutically acceptable salt, solvate or hydrate thereof for the manufacture of a medicament for the treatment of treatment-resistant forms shizofrenii.2. Use according to claim. 1, which refers to a paranoid schizophrenia, disorganized, catatonic, undifferentiated and residual type of schizophrenia, schizophreniform disorder, schizoaffective and schizotypal rasstroystvo.3. Use according to claim. 1, for the treatment of cognitive disorders in shizofrenii.4. Use according to claim. 1, wherein a resistance means it is impossible to form or when remission is not received the expected therapeutic response or no response is achieved because of the significant side effektov.5. Use according to claim. 4, in which the side effects include agranulocytosis, sedation, cognitive deficits, such as impaired attention, the different aspects of memory, manifestations of autonomic dysfunction, such as tachysystole, ortostatizm, accommodation disturbance, disturbance of gastrointestinal function, urination, weight gain, behavioral toxicity, such as incoordination, confusion, drowsiness episodes, slyunotechenie.6. A pharmaceutical composition for the treatment of treatment-resistant forms of schizophrenia, comprising as an active ingredient or or a pharmaceutically acceptable salt, solvate or hydrate thereof in a therapeutically effective kolichestve.7. The pharmaceutical composition of claim1. Применение 11-(пиперазин-1-ил)-7-фторо-8-хлоро-5Н-дибензо[b,е][1,4]диазепина, 11-(4-метилпиперазин-1-ил)-7-фторо-8-хлоро-5Н-дибензо[b,е][1,4]диазепина или фармацевтически приемлемой соли, сольвата или гидрата указанных соединений для изготовления лекарственного средства для лечения терапевтически резистентных форм шизофрении.2. Применение по п. 1, в котором под шизофренией понимается параноидный, дезорганизованный, кататонический, недифференцированный и резидуальный типы шизофрении, шизофреноформное расстройство, шизоаффективное или шизотипическое расстройство.3. Примен
